Vor Biopharma: A Funded Replication Story With Franchise Potential
Vor Biopharma Inc VOR
$18.52
▲ +0.43%
(+$0.08)
🔥 High Short Interest
Open
$18.62
Prev Close
$18.44
Day Range
$17.95 – $18.71
52W Range
$6.50 – $49.95
Market Cap
$1.15B
P/E (TTM)
1.84
Beta
1.74
EPS (TTM)
$-43.00
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-05 |
| Shares Out. | 54,190,000 |
| Website | vorbio.com/ ↗ |
| Phone | 16176556580 |
| Employees | 76 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$62.8M |
| Free Cash Flow | -$140.8M |
| Total Assets | $481.1M |
| Total Liabilities | $681.3M |
| Equity | -$200.2M |
About Vor Biopharma Inc
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
Vor Biopharma Inc is a publicly traded company under the ticker symbol VOR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-09-01)